Emerging adenosine receptor agonists: an update.

Area of Science:

• Pharmacology
• Drug Discovery
• Medicinal Chemistry

Background:

• Adenosine receptors (ARs) are crucial drug targets, with four subtypes: A(1), A(2A), A(2B), and A(3).
• Caffeine and theophylline are common antagonists of adenosine receptors.
• ARs play significant roles in various physiological processes, making them attractive therapeutic targets.

Discussion:

• Over a dozen AR agonists are undergoing clinical trials for conditions such as cardiac arrhythmias, neuropathic pain, myocardial perfusion imaging, cardiac ischemia, inflammatory diseases, and cancer.
• Approved drugs like adenosine (nonselective), regadenoson (A(2A)), and dipyridamole (indirect AR action) highlight the clinical relevance of targeting ARs.
• This editorial provides an update on the clinical trial status of AR agonists.

Key Insights:

• Adenosine receptor agonists show therapeutic potential across a wide spectrum of diseases.
• The development pipeline for AR agonists is robust, with numerous candidates in clinical investigation.
• Existing approved therapies demonstrate the feasibility and efficacy of modulating adenosine receptor pathways.

Outlook:

• Continued research and clinical trials are expected to yield new AR-targeting therapies.
• Further understanding of AR subtype selectivity will refine therapeutic strategies.
• AR agonists hold promise for addressing unmet medical needs in cardiovascular, neurological, inflammatory, and oncological conditions.